Key Highlights
- Moderna shares rallied approximately 13% to reach $67.50, marking the highest closing price since September 2024, driven by investor day presentations.
- The biotech firm unveiled mRNA-6007, its inaugural in vivo CAR-T therapy targeting autoimmune conditions such as lupus, with clinical trials slated to begin in 2027.
- A unanimous 9-0 FDA advisory committee vote endorsed Moderna’s flu vaccine for individuals aged 50 and above, with final regulatory approval anticipated by August 5, 2026.
- Jefferies analyst Andrew Tsai upgraded his price objective from $45 to $53, while Piper Sandler’s Edward Tenthoff increased his target to $77 with an Overweight stance.
- The Street’s overall rating remains Hold, with a consensus price target of $45.42 — suggesting potential downside from present price levels.
Moderna (MRNA) shares experienced a substantial rally of approximately 13% during Friday’s trading session, climbing to $67.50 and positioning the stock for its strongest close since September of last year. The performance placed MRNA at the top of the S&P 500 gainers list for the day. Intraday, the stock approached nearly 15% gains, briefly touching the $69 mark.
The driving force behind this momentum was the company’s investor day presentation, during which management outlined an ambitious expansion of its therapeutic portfolio extending far beyond its coronavirus vaccine foundation.
MRNA has now appreciated roughly 42% during the last 30 days, indicating a notable shift in market perception toward the biotech company.
The primary announcement centered on mRNA-6007, Moderna’s inaugural in vivo CAR-T therapy program. The firm intends to initiate clinical trials in 2027, with initial focus on B-cell-driven autoimmune disorders, specifically systemic lupus erythematosus.
This in vivo CAR-T approach modifies patients’ T-cells directly within their bodies, offering improved efficiency and reduced costs compared to conventional ex vivo techniques that necessitate cell extraction, laboratory modification, and subsequent reinfusion.
Moderna isn’t the only pharmaceutical player pursuing this innovative technology. Eli Lilly made a strategic acquisition of Orna Therapeutics earlier this year specifically to obtain its in vivo CAR-T capabilities. Lilly also saw a 6% stock increase on Friday, bolstered by favorable European regulatory feedback on its oral oncology medication.
Strategic Roadmap Divided Into Three Phases
Moderna presented its forward-looking plan organized into three strategic “horizons.” The initial phase concentrates on established, near-commercial assets encompassing current marketed products and advanced-stage development candidates.
Jefferies analyst Andrew Tsai projects the organization could commercialize more than seven therapeutic products spanning respiratory diseases, cancer treatments, and rare conditions within a two-year timeframe. This would represent a substantial expansion from its present three-vaccine portfolio.
Tsai highlighted anticipated Phase III melanoma trial results in the latter half of 2026 as a critical upcoming milestone, characterizing it as “a major event” for shareholder value. While maintaining a Hold rating, he elevated his price target from $45 to $53.
Another program drawing significant attention is mRNA-4194, Moderna’s inaugural cancer prevention initiative designed for Lynch syndrome patients. Additionally, the company is progressing mRNA-1195, its multiple sclerosis treatment candidate, which should yield preliminary data during late 2026.
Influenza Vaccine Provides Additional Momentum
Beyond oncology and autoimmune therapeutics, Moderna’s influenza vaccine prospect mRNA-1010 received validation when an FDA advisory committee delivered a unanimous 9-0 endorsement for approval in adults 50 years and older.
The FDA’s final regulatory determination is scheduled for August 5, 2026. Approval would provide the company with an additional commercial asset beyond the COVID-19 franchise.
Piper Sandler analyst Edward Tenthoff elevated his price objective from $69 to $77 while maintaining an Overweight recommendation, citing the substantial progress demonstrated during the investor presentation.
Despite bullish sentiment from select analysts, the broader Wall Street consensus remains at Hold, derived from two Buy ratings, 19 Hold ratings, and three Sell ratings accumulated over the previous three-month period. The mean price target stands at $45.42, implying potential downside exceeding 31% from current market prices.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
